Redcare Pharmacy stock: Berenberg raises target to EUR 102.00 for Redcare Pharmacy stock

Published on 10/22/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 results come October 29, 2026. Redcare Pharmacy stock costs EUR 79.10 on October 22, 2026 at 5:19 p.m. CEST, up 0.96 percent versus Xetra close.

Analyst target and reporting date

Berenberg raised its target from EUR 94.00 to EUR 102.00 on October 7, 2026.
Redcare Pharmacy expects 16.00 to 18.00 percent total revenue growth in fiscal year 2026.
Redcare Pharmacy stock costs EUR 79.10 at Xetra on October 22, 2026 at 5:19 p.m. CEST, plus 0.96 percent versus the Xetra close of October 21, 2026, and 4.18 percent below the 52-week high.
Redcare Pharmacy will publish its third-quarter 2026 interim statement on October 29, 2026.

Geometrisches Bauhaus-Poster mit Pillenformen, Kreuzsymbol und dem Wort PHARMA — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, gestaltet Bauhaus-Poster mit Pillenformen, Kreuzsymbol und Schriftzug PHARMA, Illustration mit AI erstellt.

Berenberg raised its Redcare Pharmacy target from EUR 94.00 to EUR 102.00 on October 7, 2026, while keeping its Buy rating, according to onvista. The new target is 28.95 percent above the EUR 79.10 price. Redcare Pharmacy stock was at EUR 79.10 on Xetra on October 22, 2026 at 5:19 p.m. CEST, plus 0.96 percent versus the Xetra close of October 21, 2026 at EUR 78.35.

Revenue guidance sets the next test

Redcare Pharmacy raised its fiscal-year 2026 total revenue growth guidance to 16.00 to 18.00 percent from 15.00 to 17.00 percent on September 28, 2026. The company also lifted its German prescription-revenue range to EUR 730.00 million to EUR 760.00 million from EUR 680.00 million to EUR 720.00 million, while keeping adjusted EBITDA margin guidance at 2.50 to 3.00 percent, according to the company release.

The guidance puts the October 29 report under a sharper test. Redcare Pharmacy said the third-quarter interim statement and conference call would take place on that date, as reported in the company release. The release also cited 56.00 percent year-over-year growth in German prescription revenue in September, a figure that gives investors a concrete benchmark for the upcoming report.

Stock remains below its yearly high

The EUR 79.10 Xetra price sits 4.18 percent below the EUR 82.55 52-week high and EUR 48.90 above the EUR 30.20 52-week low, both as of October 22, 2026. Trading volume was 54,623 shares, while market capitalization stood at EUR 1.6 billion. The price-to-earnings ratio was negative 37.82.

What matters before October 29

Second-quarter 2026 revenue reached EUR 853.50 million, up 20.00 percent from the year-earlier quarter, while net income was EUR 4.70 million, down 50.00 percent, according to Simply Wall St. That combination leaves revenue momentum clear but keeps profitability central to the next update.

Redcare Pharmacy is listed on Xetra under ticker RDC.DE and is a member of the SDAX. The company operates an online pharmacy business across several European markets, with prescription and non-prescription products forming the main revenue base.

Stock position and next date

The analyst target, the raised revenue range and the October 29 reporting date give the stock three measurable reference points. The immediate question is whether prescription growth can support the 2.50 to 3.00 percent adjusted EBITDA margin range as the revenue base expands.

At Xetra, Redcare Pharmacy stood at EUR 79.10 on October 22, 2026 at 5:19 p.m. CEST, plus 0.96 percent versus the Xetra close of October 21, 2026 at EUR 78.35.